Eric Bates, MD
This content is PDF only. Please click on the PDF icon to access.
To the editors: I am concerned that the Midgette and colleagues' meta-analysis (1) of the effect of intravenous streptokinase on mortality due to acute inferior myocardial infarction may be misinterpreted by primary care physicians. Such misinterpretation could lead to thousands of patients with inferior myocardial infarction not receiving the potential benefits attributed to thrombolytic therapy (2).
First, the conclusion that intravenous streptokinase monotherapy is ineffective in patients with inferior myocardial infarction is probably correct (3). However, it needs to be emphasized that these poor results are probably due to lower patency rates than are seen in patients with anterior myocardial
Bates E. Streptokinase for Inferior Myocardial Infarction. Ann Intern Med. ;114:701–702. doi: 10.7326/0003-4819-114-8-701
Download citation file:
Published: Ann Intern Med. 1991;114(8):701-702.
Acute Coronary Syndromes, Cardiology, Coronary Heart Disease, Emergency Medicine.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use